Anchor
Vertex completes $10 billion Crinetics acquisition, its largest deal ever
Money MovesThe $85-per-share cash deal adds an approved acromegaly drug and a late-stage endocrine pipeline to Vertex's portfolio.
Yesterday: Vertex closes $10 billion Crinetics acquisitionNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated YesterdayVertex Pharmaceuticals closed its $10 billion acquisition of Crinetics Pharmaceuticals on September 1, 2026, the largest deal in the company's history. Crinetics shareholders received $85 per share in cash, and the San Diego biotech is now a wholly owned Vertex subsidiary.
The deal gives Vertex PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly, launched in the U.S. and approved in the EU. It also adds atumelnant, an oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 trials for congenital adrenal hyperplasia, a rare hormone disorder. Vertex expects the acquisition to add to its non-GAAP operating income starting in 2029.
Why it matters
The deal makes Vertex a major endocrine-disease player, adding an approved oral acromegaly drug and a Phase 3 candidate for a rare hormonal disorder.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
$85
Cash price per Crinetics share
Every Crinetics share converted into the right to receive $85 cash when the merger closed.
$10.0B
Total equity value
Approximate equity value of the deal announced July 6, 2026.
$8.8B
Net of estimated cash acquired
Approximate purchase price after subtracting Crinetics' cash on hand.
$4.9B
Vertex's prior record acquisition
The April 2024 Alpine Immune Sciences deal; Crinetics is more than double that size.
Related Media
286 views
5:12
Crinetics Gains on Vertex Deal, Solstice Acquire Element ...
Bloomberg Podcasts
30 views
1:01:58
Vertex Pharmaceuticals Conference Call on Acquisition of ...
i101
31 views
17:05
Crinetics Pharmaceuticals Vertex Merger Analysis CRNX $ ...
Market Pulse Report
Videos from YouTube.
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
RS
R. Scott Struthers
Crinetics co-founder and chief executive officer until the acquisition closed
Resigned from the board when the merger closed September 1, 2026
Charles Wagner
Vertex Pharmaceuticals chief financial officer
Became sole director and president of the Crinetics subsidiary at closing
Reshma Kewalramani
Vertex Pharmaceuticals chief executive officer
Leading Vertex's expansion beyond cystic fibrosis
Organizations Involved
Vertex Pharmaceuticals
Public biopharmaceutical company
Acquirer; Crinetics is now a wholly owned subsidiary
Boston-based biopharmaceutical company whose cystic fibrosis drugs generate most of its revenue.
Crinetics Pharmaceuticals
Public biopharmaceutical company
Acquired; delisted from Nasdaq; operates as a Vertex subsidiary
San Diego-based biopharmaceutical company focused on oral small-molecule therapies for endocrine diseases.
Timeline
July 2026 September 2026
3 events
Latest: Yesterday
-
Vertex closes $10 billion Crinetics acquisition
Latest AcquisitionThe merger took effect. Crinetics shares converted to $85 cash each and were delisted from Nasdaq; unvested options and restricted stock units vested and were cashed out.
-
Crinetics shareholders approve the acquisition
ApprovalStockholders voted to approve the merger at a special meeting, clearing the final shareholder condition to close.
-
Vertex and Crinetics announce $10 billion merger deal
AnnouncementVertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in total equity value. Both boards approved unanimously.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
August 2022
Pfizer acquires Global Blood Therapeutics (2022)
Pfizer agreed to pay $5.4 billion for Global Blood Therapeutics, gaining Oxbryta, an approved sickle cell drug with growing sales.
Then
The deal closed in October 2022 and made Pfizer a player in sickle cell treatment.
Now
In September 2024, Pfizer withdrew Oxbryta worldwide after trial data showed higher death rates among treated patients, erasing much of the deal's value.
Why this matters now
The cautionary case for the Crinetics deal: a rare-disease drug's commercial value can vanish after closing, which is why atumelnant's Phase 3 results carry so much weight.
December 2022
Amgen acquires Horizon Therapeutics (2023)
Amgen agreed to pay $27.8 billion for Horizon Therapeutics, whose portfolio centered on rare autoimmune drugs Tepezza and Krystexxa. The U.S. Federal Trade Commission sued to block the deal.
Then
The deal closed in October 2023 after Amgen settled the FTC lawsuit over drug bundling practices.
Now
The case showed regulators will scrutinize large rare-disease acquisitions but rarely manage to block them.
Why this matters now
Like Amgen, Vertex paid a premium for a rare-disease portfolio; the Crinetics deal cleared its regulatory clearances in under two months.
April 2024
Vertex acquires Alpine Immune Sciences (2024)
Vertex agreed to pay $4.9 billion for Alpine Immune Sciences, gaining povetacicept, a late-stage drug for IgA nephropathy and other autoimmune diseases. The deal closed weeks later.
Then
The deal added a Phase 3 autoimmune drug to Vertex's pipeline and marked its first major diversification beyond cystic fibrosis.
Now
It established Vertex's pattern of buying late-stage clinical assets rather than building new drug programs from scratch.
Why this matters now
Crinetics follows the same playbook at more than twice the price, and Alpine is the benchmark for how Vertex integrates an acquired pipeline.